Gr-ADI consortium announced Philip Fowler, 22nd January 2026 Pleased and excited to be a small part of the Gram-Negative Antibiotic Discovery Innovator (Gr-ADI) consortium which was announced today. Gr-ADI is a join initiative between the Gates Foundation, Novo Nordisk Foundation, and Wellcome. Our project is headed by Dr Annette von Delft and you can read more about it here! Share this: Share on X (Opens in new window) X Share on Bluesky (Opens in new window) Bluesky Email a link to a friend (Opens in new window) Email Share on LinkedIn (Opens in new window) LinkedIn Share on Mastodon (Opens in new window) Mastodon Related antimicrobial resistance grants
antimicrobial resistance GPAS 17th May 202113th October 2021 I’ve been working on this for the last few months and very happy that we… Share this: Share on X (Opens in new window) X Share on Bluesky (Opens in new window) Bluesky Email a link to a friend (Opens in new window) Email Share on LinkedIn (Opens in new window) LinkedIn Share on Mastodon (Opens in new window) Mastodon Read More
antimicrobial resistance New preprint: compensatory mutations are associated with increased growth in resistant samples of M. tuberculosis. 22nd June 20238th December 2023 In this preprint, Viki Brunner shows how, using the large CRyPTIC dataset, she can recapitulate… Share this: Share on X (Opens in new window) X Share on Bluesky (Opens in new window) Bluesky Email a link to a friend (Opens in new window) Email Share on LinkedIn (Opens in new window) LinkedIn Share on Mastodon (Opens in new window) Mastodon Read More
antimicrobial resistance New paper: Quantitative drug susceptibility testing for M. tuberculosis using unassembled sequencing data and machine learning 14th August 202414th August 2024 This is the last paper from the initial set of CRyPTIC publications following the project’s… Share this: Share on X (Opens in new window) X Share on Bluesky (Opens in new window) Bluesky Email a link to a friend (Opens in new window) Email Share on LinkedIn (Opens in new window) LinkedIn Share on Mastodon (Opens in new window) Mastodon Read More